arrow
P

Patrick G. Morris

beaumont hospital dublin
H指数:39
被引数:8,563

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemcitabine and NAB-paclitaxel therapy in advanced pancreatic cancer
2026-01-150
OAAI
Palbociclib with adjuvant endocrine therapy in early breast cancer: five-year follow up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)

帕博西利联合辅助内分泌疗法在早期乳腺癌中的应用:全球多中心、开放标签、随机III期PALLAS试验(ABCSG-42/AFT-05/PrE0109/BIG-14-13)五年随访分析

2025-10-170
OAAI
Hybrid BAG-seq: DNA and RNA from the same single nucleus reveals interactions between genomic and transcriptomic landscapes in human tumor samples

Hybrid BAG-seq:来自同一单核的DNA和RNA揭示了人类肿瘤样本中基因组与转录组景观的相互作用

2025-10-030
OA
Cutaneous Immune-Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors for Patients With Advanced Solid Organ Malignancies

皮肤免疫相关不良事件及免疫检查点抑制剂对晚期实体器官恶性肿瘤患者的疗效

2025-09-010
OAAI
Implementation of neoadjuvant immunotherapy in stage III melanoma: a modified Delphi consensus study in a European-accredited cancer center in Ireland

在爱尔兰一家获得欧洲认证的癌症中心实施III期黑色素瘤的新辅助免疫疗法:一项改良德尔菲共识研究

2025-09-010
OAAI
Clinical benefit and cost of plasma-first next-generation sequencing in patients with newly diagnosed advanced non-small cell lung cancer in Ireland: The PLAN study

血浆优先下一代测序在爱尔兰新诊断的晚期非小细胞肺癌患者中的临床获益与成本:PLAN研究

2025-06-170
PRE
Impact of catastrophic brain injury guidelines on organ donation rates: Results of an EAST multicenter trial

灾难性脑损伤指南对器官捐献率的影响: 一项EAST多中心试验的结果

2024-12-140
PRE
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)
2024-10-070
OAAI
Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer
2024-10-040
OAAI
RET overexpression leads to increased brain metastatic competency in luminal breast cancer
2024-06-101
OAAI
Irish National Analysis of the Clinical and Economic impact of 21-gene Oncotype DX® testing in Early-Stage, 1-3 lymph node positive, Hormone Receptor positive (HR+), HER2-Negative (HER2-), Breast Cancer (BC)
2024-05-020
PRE
Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study)

早期HER2-positive乳腺癌的新辅助曲妥珠单抗deruxtecan (t-dxd) 与应答导向的确定性治疗: II期研究方案 (三叶草研究)

2024-01-179
OAAI
Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer
2023-09-270
OA